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The eCB [endoCB (cannabinoid)] system is being considered
as a novel therapeutic target for immune disorders. Cytokines
of the IL-12 (interleukin-12) family have essential functions in
cell-mediated immunity. In the present study, we have addressed
the mechanisms of action of the eCB AEA (anandamide) on the
regulation of IL-12p40 in activated microglia/macrophages. We
demonstrated that AEA can inhibit the expression of p35,
p19 and p40 subunits, which form the biologically-active
cytokines IL-12 and IL-23 in microglia stimulated with LPS
(lipopolysaccharide)/IFNγ (interferon γ ). Additionally, we have
provided evidence that AEA reduces the transcriptional activity of
the IL-12p40 gene in LPS- and IFNγ -co-activated cells, and this is
independent of CB or vanilloid receptor activation. Site-directed
mutageneis of the different elements of the p40 promoter showed
that AEA regulates IL-12p40 expression by acting on the repressor
site GA-12 (GATA sequence in IL-12 promoter). Prostamide
E2 (prostaglandin E2 ethanolamide), a product considered to be
a putative metabolite of AEA by COX-2 (cyclo-oxygenase 2)
oxygenation, was also able to inhibit the activity of the IL-12p40
promoter by acting at the repressor site. The effects of AEA and
prostamide E2 on p40 transcription were partially reversed by
an antagonist of EP2 (prostanoid receptor-type 2), suggesting the
possibility that prostamide E2 may contribute to the effects of AEA
on IL-12p40 gene regulation. Accordingly, the inhibition of COX-
2 by NS-398 partially reversed the inhibitory effects of AEA on
IL-12 p40. Overall, our findings provide new mechanistic insights
into the activities of AEA in immune-related disorders, which may
be relevant for the clinical management of such diseases.
Key words: anandamide (AEA), endocannabinoid, interleukin-12
(IL-12) p40 subunit, microglia, multiple sclerosis (MS),
prostamide E2.
INTRODUCTION
eCBs [endoCBs (cannabinoids)] are lipid signalling mediators
that play an important role in immunomodulation, and have also
been shown to be useful in the treatment of chronic inflammatory
diseases [1,2]. Microglial cells constitute a population of
‘facultative’ macrophages adapted to the neural environment
which play a critical role in CNS (central nervous system) immune
surveillance and in the initiation and maintenance of intracerebral
immune responses. Neurological disorders, such as MS (multiple
sclerosis), involve activation and even dysregulation of microglial
cells that, in addition to their phagocytic function, participate
in the regulation of non-specific inflammation as well as in
adaptive immune responses [3]. Both exogenous and endogenous
CBs have been shown to be efficient in attenuating disease
symptomatology and inflammatory reactions in chronic relapsing-
remitting EAE (experimental autoimmune encephalomyelitis)
and TMEV (Theiler’s murine encephalomyelitis virus), which
are experimental models of MS [4–9].
IL-12 (interleukin-12) is a heterodimeric cytokine formed from
two subunits, p35 and p40, which regulates innate immunity
and determines the type and duration of adaptive immunity
[10]. IL-12 is produced mainly by monocytes, macrophages and
dendritic cells, as well as brain microglia [11]. Besides forming
the IL-12p70 heterodimer, the p35 and p40 subunits may dimerize
with alternative partners to form distinct bimolecular complexes.
For example, the p19 subunit, which lacks biological activity,
combines with the p40 subunit to form IL-23, which regulates the
clonal expansion of T-cells [12]. There is evidence suggesting
that dysregulation of the IL-12 gene may contribute to the
initiation and perpetuation of various autoimmune and chronic
inflammatory diseases [13]. Despite the described reduction in
IL-12 in Legionella pneumoniae infection after administration
of the main psychoactive compound of Cannabis sativa, 9-
tetrahydrocannabinol, the mechanisms underlying this response
are still unclear [14].
The eCB family contains several structurally-related lipids
which may be synthesized and released by immune cells to act
locally in an autocrine or paracrine manner [15]. CBs mainly
act through two distinct G-protein-coupled receptors, CB1 and
CB2. However, these CB molecules have been demonstrated to
exert effects independently of CB1 and CB2 receptor activation.
These effects have been proposed to be mediated through
several unidentified receptors, or to occur in a membrane
receptor-independent fashion [1]. Within the CNS, neurons,
microglial cells and astrocytes are able to synthesize the eCBs
AEA (anandamide) and 2-arachidonoylglycerol [16–18]. During
neuroinflammation, eCBs are released mainly by microglial
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cells and exert neuroprotective actions. In particular, AEA has
been shown to protect neurons from inflammatory damage
[19]. However, despite the therapeutic relevance of eCBs, the
mechanisms of their actions on the immune system remain
unknown, and studies on the role of AEA on microglial
function are scarce. As a typical eCB, AEA is inactivated
by a reuptake system and is metabolized mainly by FAAH
(fatty acid amidohydrolase) [20]. In addition, AEA may also be
oxygenated by COX-2 (cyclo-oxygenase 2) to form prostamide
E2 (prostaglandin E2 ethanolamide) [21].
In the present study, we investigated the role of AEA in the
regulation of IL-12 and related cytokines in activated macro-
phages and microglial cells. First, we assessed whether AEA
modified the level of mRNA expression of the p19, p35 and p40
subunits of IL-12 and IL-23, as well as expression of IL12p40 pro-
tein in LPS (lipopolysaccharide)/IFNγ -activated microglial cells.
We further analysed the regulation of IL-12p40 promoter activity
by AEA using RAW 264.7 and BV-2 murine microglial cells
as cellular models. We identified the response element for AEA
action on the IL-12 p40 promoter. The involvement of CB and
vanilloid receptors in the activity of AEA was also explored,
as well as the putative involvement of the COX-2 pathway in
modulation of the effects of AEA.
EXPERIMENTAL
Materials
Culture medium and FBS (fetal bovine serum) were from
Invitrogen. AEA and LPS were from Sigma. Murine recombinant
IFNγ (interferon γ ) was from PeproTech EC (London, U.K.).
The CB antagonists SR1 (SR141716A) [N-piperidino-5-(4-
chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazol-car-
boxamide] and SR2 (SR144528) {N-(1S)-endo-1,3,3-tri-
methylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3methylphenyl)-1-
(4-methylbenzyl)-pyrazole-3-carboxamide} were supplied by
Sanofi Recherche (Montpellier, France). Prostamide E2 and
AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxilic acid) were
obtained from Cayman Chemical (Ann Arbor, MI, U.S.A.).
AH23848B was kindly supplied by GlaxoSmithKline (GSK).
Capsazepine {N-[2-(4-chlorophenyl)ethyl]-1,3,4,5-tetrahydro-
7,8-dihydroxy-2H-2-benzazepine-2-carbothionamide} was ob-
tained from Alexis Biochemicals (Lausen, Switzerland). NS-398
was purchased from Calbiochem. All other reagents were
obtained from standard suppliers.
Animals
Balb/c mice from our in-house colony (Cajal Institute, Madrid,
Spain) were used. Animals were housed in cages with filter tops in
a laminar flow hood and maintained on food and water ad lib. in
a 12 h dark/light cycle. Handling of animals was performed in
compliance with the Guidelines of Animal Care set by the
European Union (86/609/EEC).
Cell line cultures
The murine macrophage cell line RAW 264.7 was purchased
from the Center of Biological Sciences [CIB (Centro
de Investigaciones Biolo´gicas)–CSIC (Consejo Superior de
Investigaciones Cientı´ficas), Madrid, Spain]. Cells were grown
in DMEM (Dulbecco’s modified Eagle’s medium) supplemented
with 2 mM L-glutamine, 10% (v/v) FBS and 1% (v/v) penicillin/
streptomycin, and passaged every 5 days for a maximum of
30 passages. Cells were grown in a humidified environment
containing 5% CO2 and at a constant temperature of 37 ◦C. BV-2
murine microglial cells were purchased from the ICLC (Interlab
Cell Line Collection; Istituto Nazionale per la Ricerca sul Cancro,
Genoa, Italy). These cells exhibit morphological and functional
properties comparable with primary microglia.
Microglial cultures
Primary mixed glial cultures were prepared as described
previously [22]. Briefly, forebrains of newborn Balb/c mice
were dissociated mechanically, filtered through a 150 µm nylon
mesh, resuspended in DMEM containing 10% (v/v) heat-
inactivated FBS, 10% (v/v) horse serum and 1% (w/v) penicillin/
streptomycin and plated on poly-L-lysine-coated 75 cm2 flasks
(Falcon; Le Pont de Claix, France). After 15 days in culture,
the flasks were shaken at 230 rev./min at 37 ◦C for 3 h to
remove loosely adherent microglia. The supernatant was plated
on multiwell culture plates for 2 h. After this, the medium was
changed to remove non-adherent cells. Cells were grown in
a humidified environment containing 5% CO2 and held at a
constant temperature of 37 ◦C. The purity of microglial cultures
was assessed by examining cell morphology under phase-contrast
microscopy and was confirmed by immunostaining with anti-
CD11b antibody (Serotec).
Cell treatment
Prior to each experiment, DMEM containing serum was removed
and replaced with fresh serum-free DMEM. Microglia or cell
lines were stimulated with both LPS (50 ng/ml) and IFNγ
(100 units/ml) concurrently. The concentrations of the various
treatments used in the experiments were: AEA (1, 5 and 10 µM),
SR1 (1 µM), SR2 (1 µM), capsazepine (10 µM), prostamide
E2 (10 µM unless stated otherwise), NS-398 (10 µM), AH6809
(10 µM) and AH23848B (30 µM).
Plasmids
Plasmid constructs for the luciferase reporter vector were gene-
rated as described previously for the p40/pGL2B [23] and for the
p40/pXP1 [24] constructs. Mutant p40/pXP1 plasmids were gene-
rated by site-directed mutagenesis as described by Becker et al.
[24]. Mutant primer sequences are as follows (mutated bases are
underlined): ETS (E twenty-six): 5′-CCCAAAAGTCATTAA-
CTCTTAGTTC-3′; NF-κB (nuclear factor κB): 5′-GAACTT-
CTTGAAATTAGCCCAGAAGG-3′; GA-12 (GATA sequence
in IL-12 promoter) primer 1: 5′-CTCGTTTTTCTACACA-
CAC-3′; GA-12 primer 3: 5′-CTCGTTTTGATACATCCAC-
3′; and C/EBP (CCAAT/enhancer-binding protein): 5′-TGTTT-
TCAATGTTCTAACAAGTCAGT-3′.
Transfections and reporter gene analysis
The p40/pGL2B or the p40/pXP1 firefly reporter vector (200 ng/
cm2) along with a Renilla luciferase expression vector (Promega)
were transiently transfected into RAW 264.7 cells using
LipofectamineTM (Invitrogen) according to the manufacturer’s
instructions. After 18 h incubation, the medium was removed
and replaced with fresh serum-free DMEM and, after a further
2 h incubation, cells were stimulated as described in each
case. Stimulation was allowed to proceed for 18 h before cells
were harvested, washed with 0.1 M PBS (pH 7.4) and lysed
in cell lysis buffer (Promega). Luciferase activity (both firefly
and Renilla luciferase activity) was evaluated using the Dual-
Luciferase® reporter assay system (Promega), which allows
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simultaneous expression and measurement of two individual
reporter enzymes within a single system. Values were normalized
to the Renilla luciferase activity (Promega). Thus the experimental
reporter (firefly luciferase) was correlated with the effect of
specific experimental conditions, whereas the activity of the
co-transfected control (Renilla luciferase) reporter provided an
internal control. Normalizing the activity of the experimental
reporter to the activity of the internal control minimized
experimental variability due to differences in cell toxicity,
transfection efficiency and proliferation. Luciferase activity
(firefly and Renilla) was mesaured as light emission over a
period of 10 s with a standard luminometer (Sirius, Berthold
Technologies, Bad Wildbad, Germany).
Decoy oligonucleotides assay
Decoy double-stranded oligonucleotides were transfected into
RAW 264.7 cells in an attempt to interfere with the binding
of LPS- and IFNγ -activated transcription factors to their cis-
acting elements within the GA-12 sequence. The sequences of
the oligonucleotides used are as follows: decoy GA-12 wild-type,
5′-CTCGTTTTGATACACACACAGAGA-3′; and decoy GA-12
mutant 1, 5′-CTCGTTTTTCTACACACACAGAGA-3′. These
oligonucleotides were co-transfected into the RAW 264.7 cells
together with the reporter constructs. After 18 h incubation, cell
lysates were prepared and assayed for dual-luciferase activity as
described above.
Semi-quantitative RT–PCR (reverse transcription–PCR)
Total RNA from microglial primary cultures was prepared
using RNAeasy extraction columns (Qiagen). Samples (1 µg)
of total mRNA were transcribed into cDNA using the Reverse
Transcription system kit (Promega) according to the manufac-
turer’s instructions. cDNA libraries were amplified by PCR with
oligonucleotides for GAPDH (glyceraldehyde-3-phosphate de-
hydrogenase), IL-12p35 (p35) subunit, IL-12/23p40 (p40) subunit
and IL-23p19 (p19) subunit (PCR products of 800, 300, 250 and
190 bp respectively). The GAPDH primers sequences were:
sense 5′-CATTGACCTCAACTACATGGT-3′ and antisense 5′-
CATTGACCTCAACTACATGGT-3′. The p35 oligonucleotides
were: sense 5′-ATGACCCTGTGCCTTGGTAG-3′ and antisense
5′-CAGATAGCCCATCACCCTGT-3′. The p40 oligonucleotides
were: sense 5′-AGGTGCGTTCCTCGTAGAGA-3′ and antisense
5′-AAAGCCAACCAAGCAGAAGA-3′. The p19 oligonuc-
leotides were: sense 5′-GACTCAGCCAACTCCTCCAG-3′ and
antisense 5′-GGCACTAAGGGCTCAGTCAG-3′. The conditions
for amplification of GAPDH were 94 ◦C for 1 min (denaturation),
60 ◦C for 1 min (primer annealing) and 72 ◦C for 1 min
(elongation); for 35 cycles. The amplification conditions for p35
and p40 were 94 ◦C for 1 min, 50 ◦C for 1 min and 72 ◦C for
1 min; for 40 cycles. The amplification conditions for p19 were
94 ◦C for 1 min, 55 ◦C for 1 min and 72 ◦C elongation for 1 min;
for 35 cycles. The PCR products were analysed by separation on
1.5% (w/v) agarose gels. The specificity of the PCR products
was confirmed by direct sequencing, which demonstrated 100%
homology with the original sequences.
IL-12p40 ELISA
Levels of IL-12p40 in microglial culture supernatants were
quantified using specific ELISA kits purchased from Biosource
International (Camarillo, CA, U.S.A.), according to the manu-
facturer’s instructions. The assay detected >2 pg/ml and the
Figure 1 AEA represses the expression of IL-12p35, IL-12p40 and IL-23p19
subunits in activated microglia
(A) Microglial cells stimulated for 18 h with both LPS and INFγ concurrently (LPS/IFNγ )
showed an induction in the mRNA expression of p35, p40 and p19 subunits, as determined
by semi-quantitative RT–PCR. This induction was down-regulated by co-treatment with AEA
(10 µM). (B) Levels of IL-12p40 protein were determined by ELISA in the supernatant of
microglial cultures after 18 h stimulation with both LPS and INFγ . The augmented levels of
the p40 subunit in the supernatants from LPS and IFNγ -co-stimulated (LPS/IFNγ ) microglia
were diminished after co-treatment with 0, 1, 5, 10 or 15 µM AEA in a dose–response fashion.
Results are means +− S.E.M. (n = 3), with each experiment performed in triplicate. ∗ , P < 0.05
compared with control; #, P < 0.05 compared with LPS and IFNγ ; +, P < 0.01 compared with
LPS and IFNγ .
intra- and inter-assay coefficients of variations were between 3.3
and 4.5% and 5.6 and 6.7% respectively.
Statistical analysis
Results are means +− S.E.M. of at least three experiments
performed with different cell preparations. Analysis of variance
(ANOVA) followed by the Tukey test for multiple comparison
was used to determine statistical significance (95%; P < 0.05).
RESULTS
AEA negatively regulates the induction of both IL-12 (p40/p35) and
IL-23 (p40/p19) in LPS- and IFNγ -activated microglia
We first studied the microglial responses to AEA treatment when
it was co-administered with both LPS and IFNγ (50ng/ml and
100 units/ml respectively). The stimulation of murine microglial
cells with both LPS and IFNγ up-regulated the levels of mRNA
for IL-12 (p40/p35) and IL-23 (p40/p19) (Figure 1A), as shown
by semi-quantitative RT–PCR. To assess the effects of AEA on the
expression of these subunits, we treated microglial cells with LPS
and IFNγ concurrently, and with AEA. Experiments with
different AEA doses (1, 5, 10 and 15 µM) on IL-12p40 protein
c© The Authors Journal compilation c© 2008 Biochemical Society
764 F. Correa and others
Figure 2 AEA reduces IL-12p40 promoter activity independently of CB or vanilloid receptors
(A) RAW 264.7 cells were transiently transfected with a wild-type p40/pGL2B promoter gene construct. Cells were left untreated or were stimulated for 18 h with both LPS and IFNγ concurrently
(LPS/IFNγ ) in the presence or absence of different doses of AEA (0, 1, 5, 10 or 15 µM) prior to luciferase measurement. Luciferase activity was normalized to Renilla luciferase activity. Results are
means +− S.E.M. of luciferase activity (n = 12). ∗ , P < 0.02 compared with control; #, P < 0.05 compared with LPS and IFNγ ; +, P < 0.01 compared with LPS and IFNγ . (B) RAW 264.7 cells
were transiently trasfected with a wild-type p40/pGL2B promoter gene construct. Transfected cells were pre-treated with the CB antagonists SR1 or SR2 (1 µM) for 1 h, and subsequently treated
with both LPS and IFNγ concurrently (LPS/IFNγ ) and with AEA (10 µM). Luciferase activity was measured 18 h after the last treatment. Neither SR1 nor SR2 were capable of reversing the effects
of AEA on p40 promoter activity. Results are means +− S.E.M. of luciferase activity (n = 12). ∗ , P < 0.005 compared with control; #, P < 0.002 compared with LPS and IFNγ . (C) RAW 264.7 cells
were transiently transfected with 400 ng/cm2 of the wild-type p40/pGL2B promoter gene construct. Transfected cells were pre-treated with the TRPV1 antagonist capsazepine (10 µM) for 1 h and
then treated for 18 h with both LPS and IFNγ concurrently (LPS/IFNγ ) and with AEA (10 µM). Results are means +− S.E.M. of luciferase activity (n = 12). ∗ , P < 0.001 compared with control; #,
P < 0.005 compared with LPS and IFNγ .
expression (Figure 1B) led us to select the dose of 10 µM AEA
for subsequent experiments. None of the doses of AEA (1–
15 µM) exhibited cell toxicity effects, as detected by the lactate
dehydrogenase assay (results not shown). In all cases, AEA
(10 µM) was able to reverse the induction of p40, p35 and p19
subunits caused by LPS and IFNγ treatment (Figure 1A).
AEA suppresses IL-12p40 promoter activity independently of
activation of CB1, CB2 or TRPV1 (transient receptor potential
vanilloid1) receptors
Since p40 is the common subunit in both biologically active
IL-12 and IL-23, we decided to focus our study on the effects
of AEA on this particular subunit. To delineate the mechanisms
underlying the inhibitory effects of AEA on the production of
IL-12p40, its effects on LPS and IFNγ activation of the p40
promoter were explored. The RAW 264.7 murine macrophage
cell line has been extensively used as a cellular model to study
the regulation of p40 promoter activity [23–25]. RAW 264.7
cells also express CB1 and CB2 receptors, making them suitable
for studying the regulation of IL-12p40 expression by eCBs [26].
Therefore we used RAW 264.7 cells as the main cellular model
for reporter gene experiments in the present study. Cells were
transiently transfected with a luciferase reporter gene construct
driven by the wild-type IL-12p40 promoter [23]. Stimulation
with both LPS and IFNγ caused a strong induction of IL-12p40
transcriptional activity, which was significantly reversed by co-
treatment with AEA at different doses, as shown in Figure 2(A).
AEA, when applied alone, did not induce any change in p40
promoter activity. We also confirmed the inhibitory effects of
AEA on IL-12 p40 transcription in the BV-2 microglial cell
line (results not shown). The involvement of the CB receptors
CB1 and CB2 in mediating the inhibitory effects of AEA was
explored by assessing the ability of the CB1 and CB2 receptor
antagonists, SR1 and SR2 respectively, to regulate the inhibitory
effect of AEA. As shown in Figure 2(B), the presence of SR1 or
SR2 had no influence on the inhibitory effect of AEA on IL-12
p40 transcription. This suggests a lack of involvement of the
CB1 or CB2 receptors in mediating the effects of AEA. Because
several studies have demonstrated that AEA also behaves as a full
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Figure 3 AEA reduces the activity of the p40 promoter through activation of the repressor site GA-12
(A) Summary of consensus binding sites on the −300 to +68 promoter region of the IL-12p40 gene. (B) RAW 264.7 cells were transiently transfected with a reporter gene construct containing the
wild-type p40 promoter. Cells were stimulated for 18 h with both LPS and IFNγ together (LPS/IFNγ ) and with AEA (10 µM) prior to luciferase activity measurement. Non-treated transfected cells
were used as a control. Results are means +− S.E.M. of luciferase activity (n = 12). ∗∗∗ , P < 0.001 compared with control; ###, P < 0.001 compared with LPS and IFNγ . (C–E) RAW 264.7 cells
were transiently transfected with mutant p40/pXP1 reporter gene constructs carrying 2 bp mutations at the indicated (underlined) promoter sites [ETS (mETS) (C), NF-κB (mNF-κB) (D) or C/EBPβ
(mC/EBPβ) (E)], as indicated in each panel. In all three cases, induction of p40 promoter activity was lower when compared with the wild-type promoter (ETSwt, NFκBwt and C/EBPwt respectively).
The mutation was unable to interfere with the actions of AEA (10 µM) in reducing the induction caused by stimulus with both LPS and IFNγ (LPS/IFNγ ). Results are means +− S.E.M. of luciferase
activity. ∗∗∗, P < 0.001 compared with control; ##, P < 0.005 compared with LPS and IFNγ (C); ∗∗∗ , P < 0.001 compared with control; ##, P < 0.001 compared with LPS and IFNγ (D); ∗∗ ,
P < 0.002 compared with control; ##, P < 0.01 compared with LPS and IFNγ (E). (F) RAW 264.7 cells were transiently transfected with 2 bp mutated (underlined) GA-12 region (mGA-12) p40/pXP1
construct. The mutation of the repressor element interfered with the actions of 10 µM AEA. Results are means +− S.E.M. of luciferase activity. ∗∗∗ , P < 0.001 compared with control (GA-12wt). In all
cases n = 12.
agonist and a modulator of the vanilloid receptor, namely
TRPV1 [27], we investigated whether the effects of AEA could
be the result of AEA modulating TRPV1 receptors. RAW 264.7
cells transfected with the p40 promoter construct were treated
with the TRPV1 antagonist capsazepine at the effective
dose (10 µM) [27] prior to treatment with LPS, IFNγ and AEA.
As shown in Figure 1(C), pre-treatment with capsazepine was
unable to prevent the effects of AEA on p40 promoter activity.
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The GATA repressor promoter site is critical for the inhibitory
actions of AEA on IL-12p40 gene expression
Studies on the regulation of IL-12p40 promoter activity indicate
that the IL-12p40 promoter contains several binding sites for
transcription factors that contribute to gene regulation in LPS-
stimulated macrophages. The three control elements that have
been most extensively characterized bind NF-κB, C/EBPβ
and ETS transcription factor family members. In addition, a
control repressor element, termed GA-12, has been characterized
[24]. To investigate the molecular mechanisms controlling the
transcription of IL-12p40 under AEA exposure, we performed a
series of experiments to study the response elements contained
in the IL-12p40 sequence (Figures 3A and 3B). RAW 264.7 cells
were transfected with various constructs of the IL-12p40 promoter
containing 2 bp mutations in a luciferase reporter vector. These
mutant promoter constructs have been described to induce loss of
promoter activity in other models [24]. Site-directed mutagenesis
of the C/EBPβ, NF-κB and ETS sites of the IL-12p40 promoter
were unable to reverse the inhibitory effects of AEA on reporter
vector activity (Figures 3C–3E). Interestingly, when RAW 264.7
cells were transiently transfected with constructs carrying a
mutation on the GA-12 motif, AEA was unable to reverse LPS-
and IFNγ -induced activation of the p40 promoter (Figure 3F).
These results strongly suggest that the main mechanism of
action of AEA is activation of the GA-12 repressor site on the
IL-12p40 promoter. To confirm the critical role of the GATA
repressor element in inhibition by AEA, we performed decoy
oligonucleotide assays. A decoy double-stranded oligonucleotide
(with the sequence corresponding to the GATA sequence) was
generated and transfected into RAW 264.7 cells in an attempt
to interfere with binding of transcription factors modulated by
AEA to their cis-acting elements within the IL-12p40 promoter
sequence (Figure 4). The use of this decoy oligonucleotide
completely blocked the effects of AEA on IL-12p40 promoter
activity (Figure 4). To confirm further that this was a specific
effect of the decoy sequence, we used a GATA sequence decoy
oligonucleotide containing a 2 bp mutation as a control (Figure 4).
The mutated decoy oligonucleotide was unable to reverse the
effects of AEA on the down-regulation of IL-12p40 promoter
activity. These results strongly suggest that AEA reverses LPS-
and IFNγ -induced IL-12p40 expression mainly by acting on the
GA-12 repressor site.
Interactions of AEA and the COX-2 pathway: inhibition of IL-12 p40
promoter activity by prostamide E2 involves the activation of EP2
(prostanoid receptor-type 2)
Overall, our results show that the inhibitory effect of AEA on
the regulation of IL-12p40 gene transcription is mediated by a
mechanism which is independent of activation of the CB1 or
CB2 receptors. Previous evidence [21,28] indicates that COX-2
is capable of oxygenating eCB to generate new types of
prostanoids, and thus COX-2 may recognize AEA and catalyse
its conversion into prostaglandin endoperoxidase ethanolamides,
such as prostamide E2 (Figure 5A). The above findings prompted
us to investigate the effects of prostamide E2 in the regulation
of IL-12 p40. First, we studied the effects of prostamide E2 on
the induction of p40, p35 and p19 subunits caused by both LPS
and IFNγ in primary microglial cells. As shown in Figure 5(B),
prostamide E2 (10 µM) markedly reversed the LPS- and IFNγ -
induced up-regulation of p40 mRNA expression, as observed by
semi-quantitative RT–PCR. Interestingly, induction of the p35 and
p19 genes was also reduced by prostamide E2 (Figure 5B). In the
following experiments, we then addressed whether prostamide
Figure 4 Decoy GA-12 wild-type oligonucleotide is able to reverse the
effects of AEA on the activation of the repressor site at the p40 promoter
(A) Sequences of the GA-12 wild-type (dGA-12wt) and mutated (dGA-12m) decoy
double-stranded oligonucleotides used in this study. The residues which are mutated are
underlined. (B) RAW 264.7 cells were transiently transfected with wild-type p40/pXP1 reporter
gene construct with or without double-stranded decoy oligonucleotides corresponding to
wild-type GA-12 (dGA-12wt) or 2 bp mutated GA-12 (dGA-12m) region. Co-transfection of
GA-12 wild-type oligonucleotide with p40/pXP1 completely blocked the induction-reducing
effects of 10 µM AEA on p40 promoter activity, which was induced by both LPS and
IFNγ co-stimulation (LPS/IFNγ ), whereas co-transfection of dGA-12m oligonucleotide with
p40/pXP1 had no effect. Results are means +− S.E.M. of luciferase activity (n = 12). ∗∗∗ ,
P < 0.001 compared with control; ###, P < 0.001 compared with LPS and IFNγ ; +++, P <
0.001 compared with LPS and IFNγ + AEA.
E2 could regulate IL-12p40 promoter activity. To analyse this,
luciferase reporter gene assays were performed. As shown in
Figure 5(C), p40 promoter activity induced by LPS and IFNγ
was decreased in a dose-dependent manner by prostamide E2
(0.1, 1 and 10 µM). We also showed that prostamide E2 acts
on the GA-12 repressor site on the IL-12p40 promoter. Thus
when cells were transiently transfected with constructs carrying a
mutated GA-12 motif, prostamide E2 was unable to reverse LPS-
and IFNγ -induced activation of the p40 promoter (Figure 5D).
It is well known that cells of the myeloid lineage express
different types of prostanoid receptors. Therefore to investigate
whether AEA-induced inhibitory effects on IL-12p40 promoter
activity may involve the generation of prostamide E2, we used
a pharmacological approach by treating cells with AH6809, an
antagonist of EP2, as EP2 is also known to be activated by
prostamide E2 [28]. AEA and prostamide E2 were added alone
or in the presence of AH6809, together with both LPS and IFNγ
in RAW 264.7 cells. As shown in Figure 5(E), the presence of
AH6809 partially reversed the inhibitory effect of both AEA
and prostamide E2 on the transcriptional activity of IL-12p40.
Interestingly, the effect of AEA was reversed in the same manner
when EP2 was antagonized, strongly suggesting that a proportion
of the effects of AEA are mediated by EP2 activation. EP4 does
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Figure 5 Prostamide E2 reduces IL-12p40 promoter activity by activating the repressor site GA-12: involvement of EP2
(A) Scheme showing the metabolic pathway by which AEA is converted into prostamide E2. (B) Microglial cells which were stimulated for 18 h with both LPS and IFNγ (LPS/IFNγ ) showed an
increase in the expression of p35, p40 and p19 subunits at the mRNA level. When co-treated with prostamide E2 (10 µM), this induction was reduced. (C) RAW 264.7 cells were transiently transfected
with p40/pGL2B reporter gene contruct. Cells were left unstimulated or treated with both LPS and INFγ concurrently (LPS/IFNγ ) in the presence or absence of different doses of prostamide E2
(0.1, 1 or 10 µM). Prostamide E2 reduced p40 promoter activity in a dose-dependent fashion. Results are means +− S.E.M. of luciferase activity (n = 12). ∗∗∗, P < 0.001 compared with control;
#, P < 0.02 compared with LPS and IFNγ ; ##, P < 0.01 compared with LPS and IFNγ ; ++, P < 0.005 compared with LPS and IFNγ . (D) RAW 264.7 cells were transiently transfected with
wild-type p40/pXP1 reporter gene construct and transfected with or without double-stranded decoy oligonucleotides corresponding to the GA-12 wild-type or 2 bp mutated (GA-12m1) sequence.
Co-transfection of dGA-12wt with p40/pXP1 completely blocked the reducing effects of 10 µM AEA on the induction of p40 promoter activity [induced by LPS and IFNγ co-treatment (LPS/IFNγ )],
whereas co-transfection of GA-12m1 with p40/pXP1 had no effect on AEA downregulation of p40 promoter activity. Results are means +− S.E.M. of luciferase activity (n = 12). ∗∗ , P < 0.001 compared
with control; ∗ , P < 0.001 compared with control. (E) RAW 264.7 cells were transiently transfected with wild-type p40/pXP1 reporter gene construct. Transfected cells were left unstimulated or treated
with both LPS and INFγ concurrently (LPS/IFNγ ) in the presence or absence of AEA (10 µM) or prostamide E2 (10 µM). Pre-treatment with the EP2 antagonist AH6809 (10 µM) partially reversed
the effects of AEA and prostamide E2 on p40 promoter activity. Results are means +− S.E.M. of luciferase activity (n = 12). ∗∗∗ , P < 0.001 compared with control; ##, P < 0.003 compared with
LPS and IFNγ ; ++, P < 0.01 compared with LPS and IFNγ + AEA; +, P < 0.01 compared with LPS and IFNγ+prostamide E2. (F) RAW 264.7 cells were transiently transfected with wild-type
p40/pXP1 reporter gene construct. Transfected cells were left unstimulated or treated with both LPS and INFγ concurrently (LPS/IFNγ ) in the presence or absence of AEA (10 µM) or prostamide E2
(10 µM). Pre-treatment with the EP4 antagonist AH23848B (30 µM) did not modify the effects of AEA and prostamide E2 on p40 promoter activity. Results are means +− S.E.M. of luciferase activity
(n = 12). ∗, P < 0.02 compared with control; #, P < 0.05 compared with LPS and IFNγ .
not seem to be involved, since treatment with the EP4 antagonist
AH23848B did not modify the inhibitory effects of AEA or
prostamide E2 on IL-12p40 gene transcription (Figure 5F). These
results suggest that AEA could exert part of its effects on the
regulation of IL-12p40 gene transcription by the generation of
prostamide E2.
AEA and prostamide E2 down-regulate the induction of IL-12p40
protein by LPS- and IFNγ -activated microglia
Next, we attempted to delineate AEA and prostamide E2 actions
at the IL-12p40 protein level. AEA (10 µM) inhibited LPS-
and IFNγ -mediated up-regulation of p40 protein in primary
microglial cell cultures, as evaluated by ELISAs on tissue-culture
medium supernatant (Figure 6A). To explore whether AEA-
induced inhibition of IL-12p40 protein synthesis may involve
prostanoids, we co-treated microglial cells with both LPS and
IFNγ , and AEA or prostamide E2 in the presence or absence
of the EP2 antagonist AH6809. When we antagonized EP2 on
AEA-treated microglia, a partial reversion of AEA effects on the
production of IL-12p40 protein was oberved in cells stimulated
by LPS and IFNγ , as similarly seen following the addition
of prostamide E2 (Figure 6A). Again, treatment with the EP4
antagonist AH23848B (Figure 6B) was unable to modify AEA or
prostamide E2 effects on IL-12p40 protein expression.
Inhibition of the COX-2 pathway reverses the effects of AEA on both
p40 promoter activity and IL-12p40 expression
Since both AEA and prostamide E2 modulate IL-12p40 at both
the protein and promoter levels, and AEA can be oxygenated
by COX-2 to generate prostamides, we postulated that inhibition
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Figure 6 Prostamide E2 negatively modulates p40 protein levels in
activated microglial cells
(A) Microglial cells were co-treated overnight with both LPS and IFNγ (LPS/IFNγ ) and with
AEA (10 µM), prostamide E2 (10 µM) and/or EP2 antagonist AH6809 (10 µM). Antagonism
of EP2 partially blocked the effects of both AEA and prostamide E2 on p40 protein
expression. Supernatants were collected and p40 protein was measured by ELISA. Results
are means +− S.E.M. (n = 3), with each experiment performed in triplicate. ∗∗∗ , P < 0.001
compared with control; ###, P < 0.001 compared with LPS and IFNγ ; +, P < 0.05 compared
with LPS and IFNγ + AEA; ++, P < 0.005 compared with LPS and IFNγ+prostamide E2.
(B) When microglial cells were pre-treated with the EP4 antagonist AH23848B (30 µM), there
was no modification of the effects of 10 µM AEA and 10 µM prostamide E2 on p40 protein
expression as measured by ELISA. Results are means +− S.E.M. (n = 3), with each experiment
performed in triplicate. ∗∗ , P < 0.002 compared with control; #, P < 0.05 compared with LPS
and IFNγ ; ##, P < 0.005 compared with LPS and IFNγ .
of COX-2 could result in a reversion of AEA effects on the IL-
12p40 promoter. We thus treated RAW 264.7 cells with the COX-
2-specific inhibitor NS-398. In support of the contribution of
COX-2 to AEA actions, the treatment of activated RAW 264.7
cells with 10 µM NS-398 significantly reversed the inhibition of
p40 promoter activity by AEA (Figure 7A). Interestingly, NS-
398 had no effect by itself and did not modify the p40 promoter
activity when co-treated with both LPS and IFNγ . In addition, the
presence of 10 µM NS-398 was unable to reverse the effects of
prostamide E2, a downstream metabolite in the COX-2 pathway
(Figure 7A). We further confirmed these results at the protein level
in primary microglial cells, obtaining similar results to those of
p40 promoter activity (Figure 7B). Again, COX-2 inhibition with
10 µM NS-398 reversed the effects of AEA on IL-12p40 protein
expression and had no effect by itself, in the presence of LPS and
IFNγ and with prostamide E2 (Figure 7B). Overall, these results
highlight the contribution of COX-2 to AEA actions.
Figure 7 Pharmacological inhibition of COX-2 reverses the effect of AEA
both at protein and promoter levels
(A) RAW 264.7 cells were transiently transfected with a reporter gene construct containing the
wild-type p40 promoter. Cells were stimulated for 18 h with both LPS and IFN γ concurrently
(LPS/IFNγ ), and with AEA (10 µM) or prostamide E2 (10 µM), in the presence or absence of
the specific COX-2 inhibitor NS-398 (NS398; 10 µM), prior to luciferase activity measurement.
Results are means +− S.E.M. of luciferase activity (n = 9). ∗ , P < 0.05 compared with control;
#, P < 0.01 compared with LPS and IFNγ ; +, P < 0.05 compared with LPS and IFNγ + AEA;
, P < 0.01 compared with LPS and IFNγ . (B) IL-12p40 protein expression of microglia
treated with NS-398 (NS398; 10 µM). COX-2 inhibition significantly reduced the magnitude
of AEA(10 µM) inhibition on IL-12p40 protein expression (as measured by ELISA), whereas
there was no effect on prostamide E2 action, supporting the involvement of this enzyme in the
effects of AEA. Results are means +− S.E.M. (n = 3), with each experiment performed in triplicate.∗ , P<0.05 compared with control; #, P < 0.01 compared with LPS and IFNγ ; +, P < 0.05
compared with LPS and IFNγ + AEA; , P < 0.01 compared with LPS and IFNγ .
DISCUSSION
CB compounds were previously demonstrated to reduce the
development of CREAE (chronic relapsing-remitting experi-
mental autoimmune encephalomyelitis) and TMEV models of
MS [4–6]. Chronically-activated microglia and astrocytes produce
pro-inflammatory molecules that may contribute to the loss of
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oligodendrocytes, which are compromised in MS. Previously,
our group and others have reported that CB agonists inhibit the
production of pro-inflammatory molecules by CNS glial cells [7,
29–31]. In the present study, we addressed the question of whether
AEA might be involved in the regulation of IL-12 and related
cytokines on microglial cells, which are capable of producing
eCBs during CNS inflammation [18,19]. This is of interest
because of the role these cytokines play in the induction and
maintenance phases of autoimmune inflammatory demyelination
[32,33]
Our results show that activated microglial cells express the p19,
p35 and p40 subunits, therefore making the formation of IL-12
and IL-23 possible, and then raising the possibility that microglia
may contribute to Th1-skewing within the CNS. In addition, for
the first time, we demonstrated that AEA is a potent inhibitor
of mRNA expression of p19, p35 and p40 subunits and of IL-
12p40 protein release by activated microglia. IL-12 (p35/p40
subunits) and IL-23 (p19/p40 subunits) are known to play a
crucial role in the development of EAE [34]. Thus our results
support the involvement of the eCB system in the modulation of
neuroinflammatory processes, in line with its ability to limit the
immune response in animal models of MS.
The mechanisms by which AEA inhibit the production of IL-12
family cytokines in activated microglia are unknown. Because the
p40 subunit is shared by both IL-12 and IL-23, we concentrated
our studies from a mechanistic point of view on its regulation.
In activated cells, C/EBP, NF-κB and ETS are some of the
enhancer sites in the p40 promoter that may up-regulate the ex-
pression of this subunit [24]. In contrast, in resting cells, there
is a constitutively activated repressor site, called GA-12. In an
approach aimed at understanding p40 promoter regulation by
AEA, we performed site-directed mutagenesis experiments in
regions of the IL-12p40 promoter. We observed that mutations
within the core region of the GA-12 site abolished the ability
of this mutated construct to respond to AEA, strongly suggesting
that the mechanism of action of AEA is related to the activation of
this repressor site of the IL-12p40 promoter. Furthermore, decoy
oligonucleotide experiments also support the idea that AEA down-
regulates IL-12p40 expression by acting on GA-12. Our data
demonstrate for the first time that AEA-mediated down-regulation
of p40 promoter activity suggests a mechanism in which the GA-
12 repressor site is critical.
Studies on the regulation of the IL-12p40 promoter indicated
that AEA suppression of IL-12p40 promoter activity was
independent of both CB1 and CB2 receptor activation. Although
functional interactions between the eCB and vanilloid systems
have been postulated [27], our results also indicate a lack of
involvement of the vanilloid system in AEA-induced suppression
of IL-12p40. At this point, it is interesting to note that prostamide
E2, an active metabolite of AEA through COX-2 activity [35],
was able to down-regulate the transcriptional activity of IL-
12p40 in a dose-dependent manner. Although little is known
about the mechanisms of prostamide E2-induced biological
actions, it is capable of activating the prostanoid receptor EP2
[28]. Supporting this, prostamide E2-induced reversion of IL-
12p40 gene transcription by LPS and IFNγ was attenuated by
pretreatment with the prostanoid EP2 antagonist. It is important
to note that the EP2 antagonist AH6809 also caused a partial but
significant attenuation of AEA-mediated inhibition of IL-12p40
transcriptional activity and protein secretion. Moreover, AH6809
was as efficient in reversing the effects of AEA as was prostamide
E2, which would suggest that these compounds share signalling
mechanisms. Therefore the production of prostamide E2 through
metabolism of AEA by COX-2 could mediate a proportion of
the effects of AEA on IL-12 p40 regulation. Pretreatment with
the EP4 prostanoid receptor antagonist was ineffective, indicat-
ing the specificity of the effects of EP2s. However, we cannot
exclude the involvement of other mechanisms for AEA action
in IL-12 p40 regulation, including the existence of unknown CB
receptors for AEA [36], or the participation of lipid rafts. The
up-regulation of COX-2 may be important in terms of favouring
the oxygenation of AEA and generation of prostamide E2, which
would contribute to the inhibition of IL-12p40. If COX-2 plays
a role in the metabolism of AEA and generates prostamide E2
which, in turn, contributes to the inhibition of IL-12p40, then
inhibition of COX-2 should produce a positive influence on IL-
12p40 production. The suppressive effects of AEA on IL-12p40
levels were observed to be attenuated after treatment with the
specific COX-2 inhibitor NS-398, but there was no inhibition
of the effects of prostamide E2. Therefore we suggest that
during inflammation, over-expression of COX-2 may drive AEA
metabolism towards a derived prostanoid, prostamide E2, which
may contribute to the negative regulation of IL-12p40 production.
Supporting this, the results by Rockwell and Kaminski [37] show
that AEA caused a concentration-dependent inhibition of IL-2 by
murine splenocytes through the generation of a COX-2 metabolite
of AEA, independently of CB1/CB2 activation.
In the present study, AEA concentrations were used at the low
micromolar range (1–15 µM), in agreement with doses reported
in other studies [37–39]. Even though AEA levels in rat and
human plasma have been detected in the low nanomolar range,
the local concentrations of AEA under pathological conditions
could be higher. In addition, AEA has usually been measured in
normal healthy tissue and plasma samples, whereas these levels
differ substantially in inflamed or damaged tissues [19].
The eCB system is highly activated during CNS inflammation
[19]. Microglial cells are capable of producing eCBs during CNS
inflammation [18,19], and the different components of eCBs are
regulated in brain cells from MS patients [40]. Activation of the
eCB system may represent a mechanism for controlling excessive
inflammation. The inhibition of IL-12p40 may help to control and
limit the local immune response in order to prevent over-activation
of cellular immunity. Our results also suggest that excessive
COX-2 resulting from inflammation has a significant impact on
eCB-derived prostanoid signalling in immune reactivity.
Here, we present evidence that the repressor element GA-
12 is critical for AEA-mediated down-regulation of IL-12p40
promoter activity. Although the physiological relevance of these
findings needs to be established, in vivo production of prostamide
E2 has been described as occuring after AEA administration,
especially in the case of FAAH knockout mice [41]. The
identification of the mechanisms underlying the limiting effects
of eCBs on the production of pro-inflammatory cytokines such
as IL-12p40 may provide insights relevant for consideration of
the eCB system as a novel and promising target for therapeutic
treatment of autoimmune or chronic inflammatory diseases.
Our observations in microglial cells suggest that it may be of
interest to study whether eCBs can regulate IL-12 and IL-23
and then coordinate Th1/Th2 responses on CNS autoimmune
diseases, such as MS. Further studies are warranted to answer this
question.
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